1-hexadecanoyl-sn-glycero-3-phosphorylcholine | 163628-84-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-hexadecanoyl-sn-glycero-3-phosphorylcholine
• 英文别名: 1-hexadecanoyl-sn-glycero-3-phosphocholine；[(2S)-1-hexadecanoyloxy-3-hydroxypropan-2-yl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 163628-84-0
• 化学式: C₂₄H₅₀NO₇P
• 分子量: 495.637
• InChiKey: OAHJYVHIPQHKQG-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  33
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-hexadecanoyl-sn-glycero-3-phosphorylcholine 、 1-十六烷硫醇 、 N,N'-羰基二咪唑 在 三乙胺 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 生成 1-Hexadecanoyl-2-hexadecylcarbonothioyl-sn-glycero-3-phosphocholine
  参考文献：
  名称：

  Carbonothioate phospholipid analogs as substrate of phospholipases and

  摘要：

  揭示了磷脂酶、溶血磷脂酶和脂肪酶的新基质。

  公开号：

  US05801260A1

文献信息

• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。
• HYDROPHILIC FLUORINATED MOLECULES FOR LIPOSOMAL 19F MRI PROBES WITH UNIQUE MR SIGNATURES
  申请人：TEXAS CHILDREN'S HOSPITAL

  公开号：US20180154025A1

  公开（公告）日：2018-06-07

  Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19 F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19 F molecular species and to generate probes with distinct 19 F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.

  通过“点击化学”将易得的亲水性和小的有机氟基团缩合，生成具有独特的19F MR标记的非离子亲水性氟化分子。这些分子被用于制备稳定的脂质体配方，用于成像各种组织类型。这种方法旨在利用有机19F分子种类的广泛谱，生成具有不同19F MRI标记的探针，以同时评估同一目标体积内多个分子靶标。
• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• Oxidized Phospholipids
  申请人：Hermetter Albin

  公开号：US20090130648A1

  公开（公告）日：2009-05-21

  The invention relates to oxidized phospholipids having one of the general formulas (I) or (II) wherein A=O, C, NH, or S; B═O, C, NH, or S; and R 2 is selected from the group consisting of —CO—(CH 2 ) n —CH 3 ; —CO—(CH 2 ) b —CHO; and —CO—(CH 2 ) n —COOH, with n=3-7, with the proviso that in general formula (I), R 1 is selected from the group consisting of —CH 2 —(CH 2 ) n —X; a —CO—(CH 2 ) n —X with n=5-11, wherein X is a fluorophore; and in general formula (II), R 1 is selected from the group consisting of —CH═CH—(CH 2 ) n —CH 3 with n=9-15; —(CH 2 ) n —CH 3 with n=11-17; and —CO—(CH 2 ) n —CH 3 with n=10-16; and R 3 is selected from the group consisting of —CO—(CH 2 ) n —X; and —SO 2 —(CH 2 ) n —X, with n=0-5, wherein X is a fluorophore.

  本发明涉及具有以下一般式(I)或(II)之一的氧化磷脂，其中A = O，C，NH或S; B = O，C，NH或S; R2从以下组中选择：-CO-（CH2）n-CH3; -CO-（CH2）b-CHO; 和-CO-（CH2）n-COOH，其中n = 3-7，但在一般式(I)中，R1从以下组中选择：-CH2-（CH2）n-X; -CO-（CH2）n-X，其中n = 5-11，X是荧光染料; 而在一般式(II)中，R1从以下组中选择：-CH═CH-（CH2）n-CH3，其中n = 9-15; -（CH2）n-CH3，其中n = 11-17; 和-CO-（CH2）n-CH3，其中n = 10-16; 而R3从以下组中选择：-CO-（CH2）n-X; 和-SO2-（CH2）n-X，其中n = 0-5，X是荧光染料。
• Formulation comprising benzothiazolone compound
  申请人：ACHOUR Miloud

  公开号：US20160000761A1

  公开（公告）日：2016-01-07

  The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

  本发明涉及一种固体口服剂型的药物组合物，包括(R)-7-(2-(1-(4-丁氧基苯基)-2-甲基丙基氨基)-1-羟乙基)-5-羟基苯并[d]噻唑-2(3H)-酮醋酸盐。